This is the authors' abstract. We don't add key points for this paper.
A number of anti-HIV agents act by inhibiting specific steps in the lifecycle of HIV. Inhibition of reverse-transcriptase (RT), a multi-functional enzyme is an important option. The interaction of 2, 2´-(Diazinodimethylidyne)-di-(o-phenylene)-dibenzoate (HZ) with HIV1-RT was studied to explore its possible use in anti-HIV therapy. This novel hydrazine derivative undergoes strong interaction with a number of amino acid residues present in its catalytic domain, some of which are catalytically important like Asp-110, Asp-185 and Asp-186: significant among them is the Asp-186 residue that is highly conserved. Our studies may be useful in the field of structure based drug development in anti HIV therapy.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: